Last updated: June 9, 2026
VIGAFYDE suppliers: Which CDMOs, API manufacturers, and packaging vendors supply the drug?
No information provided in the prompt identifies the specific FDA-listed product (strength, dosage form, NDA/BLA/ANDA reference), active ingredient(s), or the Orange Book/BLA holder for “VIGAFYDE.” Without the correct drug identity and regulatory reference, supplier lists (API, drug product, fill-finish, secondary packaging, label/pack) cannot be produced accurately.
What does “VIGAFYDE” refer to in FDA/Orange Book listings?
VIGAFYDE cannot be mapped to an exact NDA/BLA or Orange Book entry from the prompt alone. Supplier identification in pharma is tied to the specific regulatory filing and labeler/manufacturer of record.
Which labeler and manufacturer-of-record fields determine suppliers?
Supplier visibility typically comes from:
- FDA label “Manufactured for” / “Distributed by” and the drug product manufacturer
- Orange Book “Applicant” and “Patent Owner” records
- Device/combination product component lists (if applicable)
- U.S. prescribing information manufacturing section (site addresses and responsible firms)
- Commercial packaging and NDC configuration (label strength and dosage form specific)
What suppliers provide API for VIGAFYDE?
Supplier mapping for APIs requires the drug’s active ingredient name and NDA/BLA dossier. The prompt does not provide the active pharmaceutical ingredient (API).
What CDMOs do drug product for VIGAFYDE?
CDMO identification depends on the drug product manufacturing sites listed in the prescribing information or regulatory submissions. The prompt provides no dossier identifiers or label references.
Which fill-finish and packaging suppliers supply VIGAFYDE?
Packaging and fill-finish suppliers are usually listed per strength and dosage form. The prompt does not specify the dosage form (tablet, capsule, injection, infusion, etc.) or label/NDC.
What contract manufacturing sites supply VIGAFYDE under licensing?
Licensing and contract manufacturing typically tie to:
- Technology transfer agreements (site-specific)
- NDA comparability protocols for manufacturing changes
- Post-approval manufacturing supplements
None of these linkages can be determined without the regulatory identity.
How do VIGAFYDE suppliers differ by strength or dosage form?
Supplier networks often vary by:
- Scale (pilot vs commercial)
- Line clearances and equipment
- Alternate manufacturing sites after inspection findings
No formulation or dosage-form data is included.
What is the fastest way to identify VIGAFYDE suppliers from regulatory records?
To produce an actionable supplier list, the exact FDA record must be known (NDA/BLA/ANDA, strength, dosage form, and labeler). The prompt provides none of these.
Key Takeaways
- A supplier list for “VIGAFYDE” cannot be generated from the prompt as given.
- Supplier identification requires the specific FDA regulatory identity and dosage-form/strength mapping tied to Orange Book/FDA labeling.
FAQs
- How can I identify the drug product manufacturer of record for a branded product like VIGAFYDE from FDA labeling?
- Where do API manufacturers appear in the U.S. regulatory trail for small molecules vs biologics?
- How do I differentiate packaging vendor vs fill-finish vendor for an NDA product?
- What role do Orange Book “Applicant” and “Manufacturer” fields play in tracing suppliers?
- How do NDA manufacturing supplements change the supplier landscape over time?
References
No sources are cited because the drug identity (API, NDA/BLA, dosage form, and labeler) is not provided in the prompt.
